In addition to other updates, new breakpoints have been added for cefiderocol and meropenem-vaborbactam.
ELIZABETH HIRSCH, PHARMD, RPH
Advertisement
Articles by ELIZABETH HIRSCH, PHARMD, RPH
Advertisement
Latest Updated Articles
What's New from the CLSI Subcommittee on Antimicrobial Susceptibility Testing?Published: August 13th 2018 | Updated:
Advertisement
Advertisement
Trending on Contagion Live
1
Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV Meets Primary Endpoint in Phase 3 Study
2
Zoliflodacin Emerges as a First-in-Class Oral Option Against Drug-Resistant Gonorrhea
3
Caring Holistically: NYU’s Approach to Pediatric Infectious Disease
4
FDA Approves Zoliflodacin for Uncomplicated Urogenital Gonorrhea
5
